Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GMI-1359 |
Synonyms | |
Therapy Description |
GMI-1359 is a dual inhibitor of Cxcr4 and E-selectin, which may inhibit leukemia cell adhesion and lead to apoptosis (Blood 2015 126(23):3790, PMID: 31877673, PMID: 31431613). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GMI-1359 | GMI1359|GMI 1359 | CXCR4 Inhibitor 15 | GMI-1359 is a dual inhibitor of Cxcr4 and E-selectin, which may inhibit leukemia cell adhesion and lead to apoptosis (Blood 2015 126(23):3790, PMID: 31877673, PMID: 31431613). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 exon 14 ins | leukemia | predicted - sensitive | GMI-1359 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, GMI-1359 in combination with chemotherapy resulted in significant survival benefit compared to chemotherapy alone (67% vs 30%) in cell line xenograft models of FLT3-ITD leukemia (Blood 2015 126(23):3790). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04197999 | Phase I | GMI-1359 | A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer | Terminated | USA | 0 |